NATCO Pharma board approved incorporation of a wholly-owned Chile subsidiary with investment up to US$300,000 and appointed Amit Parekh as Chief Financial Officer. The changes follow senior management transitions and align with corporate governance norms.
Source: NATCO Press Release (NSE Exchange Fillings) | Published on Feb 12, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of NATCO (NSE Exchange Filings), the company recently disclosed key developments at a corporate meeting held on 12th February 2026. The directors approved establishing a new wholly owned subsidiary in Chile with a maximum potential capital investment of USD 300,000. Changes were also made to the senior management structure, including appointing a new Chief Financial Officer.
As required by Regulation 30 and Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this was disclosed to the market. These developments represent continued changes in governance and international expansion within NATCO Pharma's (NATCO) Pharmaceutical Division.
Also read: Infosys Expands ExxonMobil AI Data Centre Partnership
The board approved incorporation of a wholly owned subsidiary in Chile with investment up to US$300,000.
Amit Parekh was appointed Chief Financial Officer with effect from 13 February 2026.
S.V.V.N. Appa Rao retired from the role of Chief Financial Officer upon superannuation on 12 February 2026.
Kalakuntla Srinivas Rao was appointed Executive Vice President – Pharma Division.
The changes were disclosed in compliance with SEBI regulations.
Also read: CESC Subsidiary Wins 250 MW SECI Wind Power Project Award
The Superannuation of S.V.V.N. Appa Rao as Chief Finance Officer was noted by the Board to occur at the close of the working day on 12 February 2026. From then, Amit Parekh will step into the Chief Finance Officer role starting from 13 February 2026. Amit has over 23 years' experience in finance and business operations, through several sectors including: healthcare, pharmaceuticals, telecommunications, chemicals and engineering.
Amit's experience includes but is not limited to financial reporting (IFRS, INDAS and USGAAP), investment and M&A activity, as well as oversight of compliance. As of 12 February 2026 Kalakuntla Srinivas Rao has been appointed Executive Vice President – Pharma Division with over 25 years' experience in pharmaceutical operation and regulatory compliance (USFDA, PMDA and MHRA).
Additionally, the Board supported creating a wholly owned subsidiary in Chile with a total investment of up to US$300,000, which will operate under the direction of the NATCO Group of Companies as an extension of NATCO's international operations in the pharmaceutical sector. The formation of a foreign subsidiary demonstrates NATCO's desire to globally establish itself, as the subsidiary will meet all regulatory requirements, including compliance with foreign currency regulations.
Particulars | Details |
Superannuation | S.V.V.N. Appa Rao retired as CFO on 12 February 2026 |
New CFO | Amit Parekh appointed from 13 February 2026 |
EVP – Pharma Division | Kalakuntla Srinivas Rao appointed from 12 February 2026 |
Overseas Expansion | Wholly owned subsidiary in Chile |
Investment Size | Up to US$300,000 |
Regulatory Framework | Regulation 30 of SEBI LODR Regulations |
NATCO's internal leadership transition and governance announcements are part of its overall corporate structure. The company has continued to conduct business in markets that are heavily regulated; because these types of markets are so heavily regulated, the importance of transparency with respect to senior management appointments continues to be of great importance in today's financial market environment.
Corporate restructurings and international expansion announcements are closely followed by market participants in relation to all other developments and events occurring within the same sector as NATCO. Therefore, trading activity as a result of corporate operations announcements or industry trends may have some impact on the NATCO share price.
The appointment of new senior management and new international expansion plans will have some degree of impact on how investors evaluate management performance and corporate strategy within the company. The NATCO share price is influenced by general market conditions, quarterly results from the company and sector conditions.
NATCO Pharma share price stands at ₹839.90 per share on the BSE as of 12 February 2026 at 15:30 PM IST, down by 1.42%.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading